Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
6.63
-0.43 (-6.09%)
At close: Oct 10, 2025, 4:00 PM EDT
6.31
-0.32 (-4.83%)
After-hours: Oct 10, 2025, 7:13 PM EDT
Kyverna Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
112
Market Cap
286.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 7.03M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKYTX News
- 16 days ago - Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS - GlobeNewsWire
- 25 days ago - Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 - GlobeNewsWire
- 6 weeks ago - Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event - GlobeNewsWire
- 6 weeks ago - Kyverna Therapeutics to Present at Upcoming Investor Conferences in September - GlobeNewsWire
- 7 weeks ago - Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026 - Benzinga
- 2 months ago - Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise - PRNewsWire
- 4 months ago - Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference - PRNewsWire